Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Severe asthma Type 2-high is a phenotype characterized by type 2-driven airway inflammation and is associated with elevated inflammatory biomarkers. According to Norihiro Harada et al. (2023), 599 of 732 severe asthma patients (81.8%) had the type 2-high phenotype. According to severe asthma type 2-high epidemiology forecast by Expert Market Research, its prevalence highlights the significant burden of eosinophilic inflammation globally.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Severe Asthma Type 2-High – Number of Cases by Year

Read more about this report - Request a Free Sample

Severe Asthma Type 2-High Epidemiology Forecast Report Coverage

Expert Market Research's “Severe Asthma Type 2-High Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of severe asthma type 2-high. It projects the future incidence and prevalence rates of severe asthma type 2-high cases across various populations. The study covers age, gender, and type as major determinants of the severe asthma type 2-high population. The report highlights patterns in the prevalence of severe asthma type 2-high over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of severe asthma type 2-high in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Severe Asthma Type 2-High Understanding: Disease Overview

Severe asthma type 2-high is a persistent form of asthma characterized by ongoing type 2 inflammation, involving cytokines such as interleukin-4, interleukin-5, and interleukin-13. This inflammatory pathway is commonly associated with elevated blood or sputum eosinophils, increased fractional exhaled nitric oxide, atopy, or elevated immunoglobulin E. Severe asthma type 2-high can present predominantly as allergic asthma, eosinophilic asthma, or overlapping allergic and eosinophilic disease. Patients may experience persistent symptoms and recurrent exacerbations despite optimized high-dose inhaled corticosteroid-based treatment.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

India

High-Risk Population

Patients with uncontrolled asthma, recurrent exacerbations, allergic disease, or eosinophilic inflammation

Key Diagnostic Method

Spirometry, supported by blood eosinophils, fractional exhaled nitric oxide, and immunoglobulin E assessment

Major Risk Factor

Tobacco smoke exposure and other airway irritants

Major gap in the market

Underdiagnosis and undertreatment

Severe Asthma Type 2-High Epidemiology Perspective

The severe asthma type 2-high epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the severe asthma type 2-high epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for severe asthma type 2-high and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to Deepak Talwar et al. (2022), asthma affects approximately 235 million people globally, while type 2-high asthma represents a substantial proportion of severe asthma populations. In India, type 2-high asthma accounted for 85% of severe asthma cases.

Gender-Specific Cases of the Disease

According to Norihiro Harada et al. (2023), females represented 54.9% of patients with type 2-high severe asthma in Japan. Similarly, Tunn Ren Tay et al. (2025) reported that 55.9% of severe asthma patients were female, indicating a substantial female representation.

Age-Specific Cases of the Disease

As per Norihiro Harada et al. (2023), the mean age of patients with type 2-high severe asthma in Japan was 64.6 years. The findings indicate that type 2-high severe asthma affects predominantly adult and older patient populations.

Ethnicity-Wise Cases of the Disease

According to Norihiro Harada et al. (2023), 30.6% of Japanese patients with type 2-high severe asthma experienced asthma exacerbations, defined by oral corticosteroid bursts, injectable steroid use, or hospitalization. In the United States, a 2025 U.S. NHANES analysis found that non-Hispanic Black children were more likely to have T2-high asthma compared with the reference population. Among 505 children with asthma, 271 (54%) were classified as T2-high.

Mortality and Survival Analysis of the Disease

According to Deepak Talwar et al. (2022), more than 80% of asthma deaths globally occur in low- and lower-middle-income countries. Although type 2-high-specific mortality was not reported, severe asthma contributes substantially to the overall asthma burden.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Allergic (Atopic) Severe Asthma

Characterized by allergen-driven Type 2 inflammation, with features such as allergic sensitization, elevated immunoglobulin E, and commonly an early-onset disease pattern.

Non-Allergic Eosinophilic Severe Asthma

Characterized by prominent eosinophilic Type 2 inflammation without a clear external allergic trigger and is commonly associated with an adult-onset disease pattern.

Mixed Allergic-Eosinophilic Severe Asthma

Characterized by overlapping allergic and eosinophilic inflammatory features, with patients demonstrating characteristics of both allergic sensitization and eosinophilic Type 2 inflammation.

Severe Asthma Type 2-High – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Severe Asthma Type 2-High Epidemiology

The severe asthma type 2-high epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

Epidemiological assessment of severe asthma in the United States includes characterization of type 2 inflammatory phenotypes using biomarkers such as eosinophils, immunoglobulin E, and fractional exhaled nitric oxide. Type 2-high disease represents an important phenotype within severe asthma and is relevant to population-level assessment of inflammatory disease burden.

Germany

Epidemiological assessment in Germany focuses on the distribution of severe asthma phenotypes and the identification of type 2 inflammatory characteristics within affected populations. Type 2-high severe asthma can be evaluated using inflammatory biomarkers and clinical characteristics relevant to disease stratification. Accordingly, the country-level epidemiological assessment centers on the recognition and characterization of Type 2-high disease within the severe asthma population.

France

In France, epidemiological assessment of severe asthma includes consideration of type 2 inflammatory patterns and their representation among patients with severe or difficult-to-treat disease. Type 2-high classification is generally linked to identifiable inflammatory characteristics, supporting phenotypic and endotypic assessment of severe asthma populations.

Italy

In Italy, epidemiological evaluation of type 2-high severe asthma involves characterization of inflammatory phenotypes among patients with severe disease. Type 2-high status provides an epidemiological basis for distinguishing patients according to inflammatory characteristics and understanding the distribution of severe asthma endotypes.

Spain

Epidemiological assessment of type 2-high severe asthma in Spain focuses on identifying patients with severe disease who demonstrate type 2 inflammatory characteristics. Such assessment supports characterization of the proportion of severe asthma attributable to type 2-high inflammatory patterns and evaluation of disease burden across affected populations.

United Kingdom

According to Hitasha Rupani et al. (2023), 93% of 388 biologic-naive patients in the Wessex Asthma Cohort of difficult asthma had Type 2-high asthma. Raised peripheral blood eosinophils and fractional exhaled nitric oxide were important components of the type 2-high classification. The study also reported that 96% of a 117-patient subset met the type 2-high definition when sputum eosinophilia was incorporated. These findings demonstrate the substantial representation of type 2-high disease among difficult-to-treat and severe asthma patients in the United Kingdom.

Japan

According to Norihiro Harada et al. (2023), 599 of 732 severe asthma patients in Japan, equivalent to 81.8%, had Type 2-high asthma. The mean age was 64.6 years, and females accounted for 54.9% of the Type 2-high population. Asthma exacerbations occurred in 30.6% of Type 2-high patients. The same study reported that asthma prevalence in Japan ranges from 6% to 10%, while severe asthma accounts for 2.4% to 12.7% of patients with asthma.

India

According to Deepak Talwar et al. (2022), approximately 2.4% of India’s population has asthma, while severe asthma is reported in fewer than 10% of adults. The study estimated that approximately 20 million Indians may have severe asthma. Type 2-high asthma accounted for 85% of severe asthma cases, with eosinophilic severe asthma representing 49% and atopic severe asthma 36%. These findings indicate a substantial Type 2-high component within the severe asthma population in India.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

A major epidemiological gap across the covered markets is the identification of patients with uncontrolled asthma who have underlying type 2 inflammation but remain insufficiently phenotyped. Greater use of blood eosinophils, fractional exhaled nitric oxide, immunoglobulin E assessment, and structured severe-asthma evaluation can improve patient identification and treatment stratification. India represents an important opportunity because substantial underdiagnosis and undertreatment of asthma remain challenges. Across developed markets, another opportunity involves improving identification of patients who remain uncontrolled despite standard inhaled therapy and may be candidates for type 2-targeted biologic therapies.

Severe Asthma Type 2-High: Treatment Overview

Severe asthma type 2-high treatment focuses on controlling airway inflammation, reducing exacerbations, improving symptom control, and minimizing systemic corticosteroid exposure. Standard management includes optimized inhaled corticosteroid and long-acting beta2-agonist therapy, appropriate inhaler technique, adherence assessment, trigger avoidance, and management of relevant comorbidities. For patients with persistent type 2 inflammation and inadequate disease control, biologic therapy may be added according to the patient's inflammatory phenotype. Type 2-targeted therapies include anti-immunoglobulin E, anti-interleukin-5, anti-interleukin-5 receptor, anti-interleukin-4 receptor alpha, and anti-thymic stromal lymphopoietin therapies.

Key Questions Answered

  • What is the current and projected burden of severe asthma type 2-high across the 8 major markets?
  • Which countries across the 8 major markets account for the highest severe asthma type 2-high patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of severe asthma type 2-high across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of severe asthma type 2-high across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of severe asthma type 2-high across the 8 major markets?
  • How do major comorbidities and risk factors influence severe asthma type 2-high epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of severe asthma type 2-high across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the severe asthma type 2-high landscape across the 8 major markets?
  • Which therapeutic areas linked to severe asthma type 2-high are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the severe asthma type 2-high epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on severe asthma type 2-high epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for severe asthma type 2-high across the 8 major markets?

Scope of the Severe Asthma Type 2-High Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of severe asthma type 2-high based on several factors.
  • Severe Asthma Type 2-High Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The severe asthma type 2-high report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Asthma Treatment Market

Asthma Epidemiology

Asthma Pipeline

Eosinophilic Asthma Drug Pipeline

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us